Square Pharmaceuticals Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 3/6
Square Pharmaceuticals has been growing earnings at an average annual rate of 11%, while the Pharmaceuticals industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 9.7% per year. Square Pharmaceuticals's return on equity is 16.7%, and it has net margins of 29%.
Key information
11.0%
Earnings growth rate
11.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | 9.7% |
| Return on equity | 16.7% |
| Net Margin | 29.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Square Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 67,469 | 19,599 | 14,761 | 0 |
| 30 Sep 23 | 65,137 | 19,480 | 14,126 | 0 |
| 30 Jun 23 | 62,748 | 18,980 | 13,599 | 0 |
| 31 Mar 23 | 62,020 | 18,856 | 13,902 | 0 |
| 31 Dec 22 | 60,782 | 19,143 | 13,098 | 0 |
| 30 Sep 22 | 58,791 | 18,680 | 12,597 | 0 |
| 30 Jun 22 | 57,598 | 18,157 | 12,118 | 0 |
| 31 Mar 22 | 56,713 | 18,526 | 11,181 | 0 |
| 31 Dec 21 | 54,834 | 17,819 | 10,825 | 0 |
| 30 Sep 21 | 53,004 | 17,012 | 10,425 | 0 |
| 30 Jun 21 | 50,703 | 15,947 | 10,034 | 0 |
| 31 Mar 21 | 49,021 | 14,484 | 9,406 | 0 |
| 31 Dec 20 | 48,395 | 14,237 | 9,205 | 0 |
| 30 Sep 20 | 47,158 | 13,933 | 9,023 | 0 |
| 30 Jun 20 | 45,876 | 13,354 | 8,855 | 0 |
| 31 Mar 20 | 46,360 | 13,733 | 8,775 | 0 |
| 31 Dec 19 | 45,138 | 13,236 | 8,483 | 0 |
| 30 Sep 19 | 44,785 | 12,831 | 8,266 | 0 |
| 30 Jun 19 | 44,034 | 12,646 | 8,038 | 0 |
| 31 Mar 19 | 42,322 | 12,168 | 7,454 | 0 |
| 31 Dec 18 | 41,252 | 12,025 | 7,479 | 0 |
| 30 Sep 18 | 40,328 | 11,754 | 7,208 | 0 |
| 30 Jun 18 | 39,654 | 11,594 | 6,996 | 0 |
| 31 Mar 18 | 39,474 | 11,667 | 6,849 | 0 |
| 31 Dec 17 | 39,131 | 11,622 | 6,480 | 0 |
| 30 Sep 17 | 37,978 | 11,222 | 6,330 | 0 |
| 30 Jun 17 | 36,543 | 10,637 | 6,193 | 0 |
| 31 Mar 17 | 35,584 | 10,330 | 6,102 | 0 |
| 31 Dec 16 | 34,534 | 9,893 | 5,490 | 0 |
| 30 Sep 16 | 33,448 | 9,639 | 5,315 | 0 |
| 30 Jun 16 | 33,074 | 9,199 | 5,371 | 0 |
| 31 Dec 15 | 29,642 | 7,770 | 4,966 | 0 |
| 30 Sep 15 | 28,400 | 7,091 | 4,792 | 0 |
| 30 Jun 15 | 27,531 | 6,411 | 4,711 | 0 |
| 31 Mar 15 | 25,979 | 6,032 | 5,091 | 0 |
| 31 Dec 14 | 25,858 | 5,060 | 4,632 | 0 |
| 30 Sep 14 | 25,511 | 5,122 | 4,447 | 0 |
| 30 Jun 14 | 24,176 | 5,002 | 4,337 | 0 |
| 31 Mar 14 | 23,268 | 4,945 | 4,162 | 0 |
| 31 Dec 13 | 23,018 | 4,988 | 4,245 | 0 |
| 30 Sep 13 | 22,304 | 4,677 | 4,174 | 0 |
| 30 Jun 13 | 21,540 | 4,477 | 3,912 | 0 |
Quality Earnings: SQURPHARMA has high quality earnings.
Growing Profit Margin: SQURPHARMA's current net profit margins (29%) are lower than last year (31.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SQURPHARMA's earnings have grown by 11% per year over the past 5 years.
Accelerating Growth: SQURPHARMA's earnings growth over the past year (2.4%) is below its 5-year average (11% per year).
Earnings vs Industry: SQURPHARMA earnings growth over the past year (2.4%) exceeded the Pharmaceuticals industry -2.6%.
Return on Equity
High ROE: SQURPHARMA's Return on Equity (16.7%) is considered low.